Related Experiment Videos
Imatinib: a targeted clinical drug development
Renaud Capdeville1, Sandra Silberman
1Novartis Oncology, Novartis Pharma AG, Basel, Switzerland; and Novartis Oncology, Novartis Pharmaceutical Corp, Florham Park, NJ, USA.
Abstract:
Imatinib (Gleevec) (formerly STI571) is an orally bioavailable rationally developed inhibitor of the tyrosine kinases Bcr-Abl, Kit, and platelet-derived growth factor receptor (PDGFR). In 4 years of clinical development, more than 12,000 patients have been treated in the clinical development program. Imatinib was first shown to be highly effective in the treatment of all stages of chronic myelogenous leukemia (CML). Moreover, preliminary results of a randomized study have demonstrated superior efficacy and safety of first-line imatinib therapy compared with a combination of interferon and cytarabine. Imatinib has also been shown to be the only effective drug therapy in the treatment of patients with metastatic gastrointestinal stromal tumors expressing the stem cell factor (SCF) receptor Kit. This review outlines the successive steps in the clinical development of this new, targeted anticancer agent.
Insights
Imatinib (Gleevec) is a targeted therapy effective for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). It shows superior efficacy and safety compared to traditional treatments.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Imatinib (Gleevec) is a rationally designed tyrosine kinase inhibitor targeting Bcr-Abl, Kit, and PDGFR.
- Over 12,000 patients have participated in imatinib's clinical development program.
- Targeted cancer therapies represent a significant advancement in oncology.
Purpose of the Study:
- To review the clinical development of imatinib as a targeted anticancer agent.
- To highlight imatinib's efficacy in specific hematologic and solid tumors.
- To provide an overview of imatinib's mechanism of action and therapeutic applications.
Main Methods:
- Review of clinical trial data and published literature on imatinib.
- Analysis of imatinib's efficacy and safety profiles in various cancer types.
- Examination of imatinib's molecular targets and their role in cancer progression.
Main Results:
- Imatinib demonstrates high efficacy in all stages of chronic myelogenous leukemia (CML).
- Preliminary data suggest imatinib is superior to interferon and cytarabine in CML treatment.
- Imatinib is the only effective therapy for metastatic gastrointestinal stromal tumors (GIST) with Kit mutations.
Conclusions:
- Imatinib is a highly effective targeted therapy for CML and GIST.
- Imatinib represents a paradigm shift in cancer treatment through targeted molecular inhibition.
- Further clinical development continues to explore imatinib's potential in other malignancies.